News
Immupharma PLC - Final Results
·Research and development expenses of £2.0 m. ·Cash balance at 31 December 2022 of £0.7 m. ·Successful subscription and placing, raising in total £2.0 m- August 2022.
h1{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:12.0pt;font-family:"Times New ...